← Eichor
Study identifier: NCT06114043 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Operative Versus Non-operative Treatment for Mild to Moderate Hallux Valgus Deformity

Condition: Hallux Valgus Deformity  ·  Sponsor: Ostfold Hospital Trust

PhaseNA
Planned participants120
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersYes

About this study

The goal of this randomized controlled trial is to investigate operative treatment versus conservative treatment in participants suffering from mild to moderate hallux valgus deformity. The main question it aims to answer are; Is surgery superior to conservative treatment? The participants will be randomized in to two groups, operative and conservative group. Investigators will compare the groups measuring the clinical results using the patient-reported outcome measure (PROM) Manchester-Oxford Foot Questionnaire (MOxFQ), Visual analog scale (VAS), likert scale 0-5. Participants will be observed for a period og two years.

This description comes directly from the study's public registry record.

Talk to the study team

Marius Molund  ·  90093988  ·  marius.molund@so-hf.no

Mikaela E Hamre  ·  +4741273586  ·  mikaela.engaras.hamre@so-hf.no

Always discuss trial participation with your own doctor first.

Locations (1)

Østfold Hospital TrustSarpsborg, NorwayRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06114043